---
title: "Amarin regains compliance with Nasdaq minimum bid price requirement"
url: "https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-04-29"
section: "Listings"
tickers: "NASDAQ:AMRN"
source: "https://www.sec.gov/Archives/edgar/data/897448/000095017025060165/amrn-ex99_1.htm"
summary: "Nasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq."
---

By the aibio.space news desk.

Sources

- [Amarin Corporation plc 8-K (2025-04-29)](https://www.sec.gov/Archives/edgar/data/897448/000095017025060165/amrn-ex99_1.htm)

[AMRN](https://aibio.space/companies/amarin/)

2025-04-29

# Amarin regains compliance with Nasdaq minimum bid price requirement

Tickers [AMRN](https://aibio.space/companies/amarin/)

Nasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.

## Key facts

- **Company**: Amarin Corporation plc (NASDAQ: AMRN)

- **News type**: Listings

- **Primary source**: [Amarin Corporation plc 8-K (2025-04-29)](https://www.sec.gov/Archives/edgar/data/897448/000095017025060165/amrn-ex99_1.htm)

*Marble steps and columns of a supreme court building. CC0, via rawpixel. The picture shows the field, not the companies named.*

Amarin Corporation plc (NASDAQ: [AMRN](https://aibio.space/companies/amarin/)) announced on April 29, 2025 that it has regained compliance with Nasdaq's continued listing standard for minimum share price under Rule 5550(a)(2). The release's subheading says the compliance follows an ADS ratio change.

The company received confirmation from the Nasdaq Listing Qualifications Department on April 29, 2025. Nasdaq said that as of April 28, 2025 the company's common stock had maintained an average closing share price of at least $1.00 over the last 10 consecutive business days ending on that date.

As a result, Amarin's shares are no longer considered to be below the minimum bid price requirement of Rule 5550(a)(2). Nasdaq now considers the matter closed. Amarin said it is in full compliance with all Nasdaq listing requirements and will continue to be listed and traded on Nasdaq.

President and Chief Executive Officer Aaron Berg called the news "an important step for the Company by maintaining our public listing on the Nasdaq Capital Market."

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

AMRN

Amarin Corporation plc

NASDAQ · Ireland

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Amarin regains compliance with Nasdaq minimum bid price requirement", 2025-04-29, https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/